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Objective: The aim of this study was to evaluate the effects of inhaled nitric 
oxide in patients with critical pulmonary perfusion after Fontan-type 
procedures and bidirectional Glenn anastomosis. Methods: Inhaled nitric 
oxide (mean 4.1 - 0.7 ppm, 1.5 to 10 ppm) was administered in 13 patients 
(mean age 5.6 --- 1.6 years, 1.5 to 17 years) with critical pulmonary 
perfusion (central venous pressure >20 mm Hg or transpulmonary pres- 
sure gradient >10 mm Hg) in the early postoperative period after total 
cavopulmonary connection (n = 9) or after bidirectional Glenn anastomo- 
sis (n = 4). Results: In patients after total cavopulmonary connection 
inhaled nitric oxide therapy decreased central venous pressure by 15.3% --- 
1.4% (p = 0.0001) and transpulmonary pressure gradient by 42% _ 8% 
(p = 0.0008) and increased mean systemic arterial and left atrial pressures 
by 12% ± 3.6% (t7 = 0.011) and 28% -+ 8% (p = 0.007), respectively. Arterial 
and venous oxygen saturations improved by 8.2% -.+ 1% (p = 0.005) and 
14% -+ 4.3% (p = 0.03), respectively. In patients after bidirectional Glenn 
anastomosis nhaled nitric oxide therapy resulted in a decrease of central 
venous pressure by 22% -+ 1% and of the transpulmonary pressure gradient 
by 55% - 6% and improved arterial and venous oxygen saturations by 37% 
+ 29% and 11% --- 3%, respectively. Mean systemic arterial and left atrial 
pressures remained nearly unchanged. No toxic side effect was observed in 
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any patient. Conclusion: Inhaled nitric oxide may play an important role in 
the management of transient critical pulmonary perfusion caused by 
reactive elevated pulmonary vascular resistance in the early postoperative 
period after Fontan-type operations and bidirectional Glenn anastomosis. 
(J Thorac Cardiovasc Surg 1997;113:435-42) 
R ecently, inhaled nitric oxide (NO) has been reported as a selective pulmonary vasodilator in 
different experimental models of pulmonary hyper- 
tension. 1-3 Clinical studies have demonstrated that 
inhaled NO decreased elevated pulmonary artery 
pressure, pulmonary vascular esistance (PVR), and 
ventilation-perfusion mismatch in adults with adult 
respiratory distress syndrome, 4 in neonates with 
persistent pulmonary hypertension 5' 6 or with severe 
hypoxemic respiratory failure, 7 and in children with 
congenital heart disease complicated by pulmonary 
hypertension. 8 Inhaled NO even in low doses has 
been shown to reduce elevated pulmonary artery 
pressure and PVR in infants and children with 
severe pulmonary hypertension after cardiac opera- 
tions without relevant negative side effects on sys- 
temic circulation. TM 
In patients after Fontan-type operations or bidi- 
rectional Glenn anastomosis pulmonary perfusion 
and consequently cardiac output are critically de- 
pendent on low PVR and normal systemic ventric- 
ular functionJ 2-15 In particular, in the early postop- 
erative period even a small reactive increase of PVR 
may cause deleterious systemic venous hypertension 
associated with resistant low cardiac output syn- 
drome despite a technically successful operation. 16 
Previously, only a few cases of inhaled NO treat- 
ment after Fontan operations 17-19 and bidirectional 
Glenn anast0mosis 2° have been reported. We 
present our experience with inhaled NO in a series 
of patients with critical pulmonary perfusion in the 
early postoperative period after Fontan-type proce- 
dures and bidirectional Glenn anastomosis. 
Patients and methods 
Patients. Thirteen patients (5 girls and 8 boys) with 
single-ventricle physiology were included in this study. 
The mean age was 5.6 + 1.6 years (1.5 to 17 years) and the 
mean body weight was 20.7 -+ 4.3 kg (9.5 to 52 kg). The 
demographic data, diagnoses, and preoperative hemody- 
namic parameters determined by catheterization are sum- 
marized in Table I. 
Operation and intensive care. Four patients (patients 1
through 4) underwent bidirectional cavopulmonary Glenn 
anastomosis is and nine patients (patients 5 through 13) 
total cavopulmonary connection according to the tech- 
nique of de Leval and colleagues. 21 In seven patients 
undergoing total cavopulmonary connection a fenestra- 
tion of the interatrial baffle 22 with a diameter of 3 or 4 mm 
was created because of the presence of more than two risk 
factors. 12 Mean aortic crossclamp time and mean time of 
cardiopulmonary b pass were 41 _+ 5 minutes (24 to 78 
minutes) and 118 _+ 11 minutes (57 to 188 minutes), 
respectively. 
Surgical repair and anesthetic management, aswell as 
postoperative intensive therapy, were unchanged from 
normal practice for the study. In all patients one arterial 
line for continuous blood pressure monitoring and inter- 
mittent blood gas measurements and two central venous 
lines were placed, one in the superior caval vein for 
central venous pressure (CVP) recording and one in the 
inferior caval vein for fluid and drug administration. 
Additionally a 2F catheter was inserted into the left 
atrium for pressure tracings. After operation CVP, left 
atrial pressure (LAP), systemic arterial pressure, systemic 
arterial saturation by pulse oximetry, the electrocardio- 
gram, and the partial pressure of end-tidal carbon dioxide 
(Petcoa) were continuously recorded on a multichannel 
monitor (SMU 612, Hellige Corp., Freiburg, Germany). 
Dopamine (4 to 6 p~g/kg per minute) and dobutamine (6 
to 10/xg/kg per minute) or epinephrine (0.05 to 0.25/xg/kg 
per minute) were used as inotropic agents, and in cases of 
severely impaired systemic ventricular function milrinone 
(0.4 to 0.7 txg/kg per minute) was added. Continuous 
infusions of fentanyl (0.015/~g/kg per minute), midazolam 
(0.25 mg/kg per hour), and vecuronium (0.1 mg/kg per 
hour) were administered for sedation, analgesia, and 
relaxation, respectively. All patients were nasotracheally 
intubated and the lungs ventilated with pressure-con- 
trolled mechanical ventilators (Veolar, Hamilton Medical 
Inc., Rhfizuns, Switzerland, and Babylog 8000, Drfiger 
Company, Ltibeck, Germany) to achieve arterial carbon 
dioxide pressure levels between 35 and 40 mm Hg and pH 
values greater than 7.35. Daily chest x-ray films were taken 
to assess lung perfusion and inflation and signs of pulmo- 
nary parenchymal disease and pleural effusions. 
NO administration. NO gas was obtained in a mixture 
with nitrogen at 450 ppm NO (Pulmonix forte, Messer 
Griesheim, Austria). NO was administered with use of a 
microprocessor-controlled system that allows NO delivery 
at concentrations from 1 to 40 ppm and continuous 
inspiratory measurements of NO and its toxic oxidative 
product nitrogen dioxide (NO;) by the chemolumines- 
cence method (Pulmonox system, Messer Griesheim, Aus- 
tria). A flow box incorporated into the inspiratory limb of 
the ventilatory circuit transfers the inspiratory flow rate of 
the ventilator to the Pulmonox system, which adapts the 
dosage on a continuous basis. NO was administered into 
the inspiratory limb of the ventilatory circuit 20 cm 
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Tab le  I. Demographic and preoperative data 
Age Weight PAP/rn PVRI RAP Sao 2 
Subjects (yr) (kg) Major diagnoses (rnrn Hg) (U" m 2) (ram Hg) (%) 
Glenn anastomosis (n = 4) 
1 1.5 11.3 
2 1.5 11 
3 2 9.5 
4 1.8 12.5 
TCPC (n = 9) 
5 2 10.5 
6 2.7 12.5 
7 15 46 
8 1.7 9.5 
9 3.5 12.5 
10 7 28 
l l  3.4 14.2 
12 14 52 
13 17 40 
PA, VSD, hypopl. LV 8 0.7 5 85 
TGA, VSD, hypopl. RV 8 2.5 3 72 
DILV, PA 16 1.8 6 80 
TA 9 2.4 5 80 
TA, VSD 15 1.4 8 77 
VSD, hypopl. RV 16 1 9 84 
TA, PA 9 2 3 82 
Criss-cross heart, PA 12 0.5 8 80 
DILV, PA 9 1.5 5 82 
DORV, MA 11 1.8 8 76 
DORV, VSD, hypopl. 12 1.8 6 88 
LV 
DORV, TGA, SA, single 12 1.4 8 85 
AV valve 
DORV, MA 12 2 12 70 
PAP~m, Mean pulmona U artery, pressure; PVR[, pulmonary vascular resistance index; RAP, right atrial pressure; PA, pulmonary atresia; VSD, ventricular 
septal defect; hypopl. L~ hypoplastic left ventricle; TGA, transposition f the great arteries; hypopl. RV, hypoplastic right ventricle; DILV,, double-inlet left 
ventricle; TA, tricuspid atresia; TCPC, total cavopulmonary connection; DORV,, double-outlet right ventricle; MA, mitral atresia; SA, single atrium. 
Tab le  II. Hemodynamic parameters, oxygen saturation and end-tidal carbon dioxide values in nine patients 
with total cavopulrnonary connection after exposure to inhaled NO compared with baseline 
NO I p Value* NO 0 p Value? NO H 
CVP (mm Hg) 17.6 +- 1 (14-22) 0.0001 21 + 1.1 (16-26) 0.0001 17.8 + 1 (14-22) 
LAP (mm Hg) 9.7 -- 0.9 (6-14) 0.0006 7.6 + 1.1 (3-14) 0.0011 9.2 + 1.1 (5-16) 
TPG (mm Hg) 7.9 +_ 0.6 (6-12) 0.0001 13.5 _+ 0.8 (10-18) 0.0013 7.7 _+ 1 (4-12) 
SAP (mm Hg) 64 ± 3 (56-82) 0.031 59 _+ 4 (43-79) 0.0054 65 +_ 4 (54-86) 
HR (beats/±in) 130 _+ 7 (98-155) 131 _+ 7 (97-153) 130 _+ 7 (97-152) 
Sao: (%) 94 ± 1 (88-98) 0.0004 86 ± 1 (82-93) 0.0004 94 ± 1 (88-98) 
Svo2 (%) 71 ± 3 (61-78) 0.037 63 ± 3 (58-72) 0.023 72 ± 2 (65-78) 
Petco 2 (ram Hg) 32 _+ 1.3 (26-39) 0.0005 29 +_ 1.6 (22-37) 0.0005 32 ± 1.3 (25-39) 
Data are expressed as mean values plus or minus the standard error of the mean (range). 
NO I, NO II, Exposure to NO; NO O, baseline; TPG, transpulmonary p essure gradient (CVP - LAP); SAP, mean systemic arterial pressure; HR, heart rate; 
Svos, mixed venous blood oxygen saturation. 
*NO 0 vs NO I. 
tNO 0 vs NO II. 
proximal to the endotracheal  tube with use of an airway 
sampling adapter (Engstr6m sampling adapter, Gambr6 
EngstrOm, Bromma, Sweden). The system was calibrated 
before each treatment and measurement  with special 
calibration gases. Methemoglobin was measured 2 hours 
after the start of NO therapy and then two to three times 
daily (CO-Oxylite AVL  912, AVL  Corp., Graz, Austria). 
Study protocol. Indication for treatment with NO was a 
transpulmona13~ pressure gradient (CVP - LAP) of more 
than 10 mm Hg or a CVP more than 20 mm Hg in the early 
postoperative period after exclusion of relevant atrioventric- 
ular valve insufficiency, severe impairment of systemic ven- 
tricular function, and pulmonary venous or arterial obstruc- 
tion by two-dimensional transthoracic or transesophageal 
echocardiography. NO was delivered at the lowest effective 
dose to obtain a transpulmonary pressure gradient less than 
10 mm Hg or a decrease in the transpulmonary pressure 
gradient of more than 20%. After 12 to 18 hours of stable 
hemodynamics the first NO switch on/off trial was done. 
Inhaled NO administration was discontinued for 5 minutes 
to perform a baseline study, followed by a continuation of 
NO treatment at the same dose as used in the initial period. 
Ventilation parameters (mean airway pressure, mean 9 _+ 
0.5 cm H20 , range 7 to 14 cm H20 ) and fractional inspired 
oxygen concentration (mean 0.8 _+ 6, range 0.4 to 1.0) and 
inotropic support remained unchanged uring the study 
period. A complete set of measurements was recorded 5 
minutes after the beginning of each period including heart 
rate, mean systemic arterial pressure, CVP, LAP, arterial 
oxygen saturation (Sa%), venous o~gen saturation, and 
Petco 2. 
Weaning of the patient from inhaled NO therapy was 
attempted every day by decreasing NO concentrat ion by 
50% and finally discontinuing NO administrat ion when 
CVP 
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Fig. 1. CVP after exposure to inhaled NO (NO [, NO II) 
compared with baseline value (NO 0). 
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Fig. 2. Transpulmonary pressure gradient (CVP - LAP) 
after exposure to inhaled NO (NO I, NO II) compared 
with baseline value (NO 0). 
the inhaled NO dose was only 1 ppm. If weaning from 
inhaled NO resulted in worsening of the cardiorespiratory 
state, the patients were first weaned from ventilatory 
support; after successful extubation NO was administered 
by means of nasal prongs. The study protocol was ap- 
proved by the local ethics committee. Informed consent 
concerning the nature of the study was obtained from the 
parents of all patients. 
Statistical analysis. All data are expressed as mean + 
standard error of the mean (range) and as mean percent- 
age change +- standard error of the mean. The effects of 
NO on hemodynamic parameters and oxygenation were 
compared with baseline findings by means of the two- 
tailed paired Student's t test. A p value < 0.05 was 
considered statistically significant. 
Results 
Before the start of NO inhalation therapy, mean 
CVP and mean transpulmonary pressure gradient 
were 22 _+ 0.9 mm Hg (16 to 25 mm Hg) and 14.2 _+ 
0.7 mm Hg (11 to 19 mm Hg), respectively. 
In the patient group undergoing total cavopulmo- 
nary connection (n = 9) inhaled NO therapy signif- 
icantly decreased CVP by 15.3% -+ 1.4% (p = 
0.0001) and the transpulmonary pressure gradient 
(CVP - LAP) by 42% _+ 8% (p = 0.0008). LAP and 
mean systemic arterial pressure values increased by 
28% _+ 8% (p = 0.007) and 12% _+ 3.6% (p = 
0.011), respectively. Heart rate remained unchanged 
during the study period. Inhaled NO improved Sao 2 
values by 8.2% + 1% (p = 0.005) and venous oxygen 
saturation values by 14% _+ 4% (p = 0.03), whereas 
Petco 2 values increased by 12% _+ 3% (p = 0.002) 
(Table II, Figs. 1 through 4). 
In four patients with bidirectional Glenn anasto- 
mosis (Table II I) NO inhalation therapy resulted in 
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Fig. 3. Mean systemic arterial pressure (SAP) after expo- 
sure to inhaled NO (NO I, NO II) compared with baseline 
values (NO 0). 
a decrease of CVP and of the transpulmonary 
pressure gradient by 22% _+ 1% and 55% + 6%, 
respectively. After NO exposure values of LAP 
and mean systemic arterial pressure increased by 
13% + 7% and 5.5% ± 2%, respectively. Inhala- 
tion of NO improved Sao2 values by 37% ± 29% 
and venous oxygen saturation values by 11% _+ 
3%, whereas Petco 2 values increased by 12% -+ 
6% (Figs. 1 through 4). In a 1.8-year-old patient 
with tricuspid atresia (patient 4) the most signifi- 
cant improvement of Sao 2 values from 31% to 
69% was observed, whereas CVP decreased from 
21 to 15 turn Hg. 
Patients were treated with inhaled NO for 106 _+ 
19 hours, ranging from 12 to 264 hours. Mean NO 
concentration was 4.1 ± 0.7 ppm, ranging from 1.5 
to 10 ppm. Methemoglobin levels measured 3 to 4 
times daily in each patient ranged from 0.6% to 
SaO2 
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Fig. 4. Sao 2 after exposure to inhaled NO (NO I, NO II) 
compared with baseline values (NO 0). 
2.3% (mean 1.2% _+ 0.16%) and NO 2 concentra- 
tions never exceeded 0.1ppm. No other side effects 
were observed. In three patients NO inhalation 
therapy was continued by means of nasal prongs for 
0.5 to 48 hours after extubation. The mean duration 
of mechanical ventilation was 6.0 _+ 1.0 days (1.5 to 
18 days). In one patient, who required artificial 
ventilation for 18 days, the postoperative course was 
complicated by septicemia ssociated with multior- 
gan failure. One patient died of cerebral hemor- 
rhage 5 days after weaning from NO inhalation with 
a stable hemodynamic condition on postoperative 
day 10. 
Discussion 
Postoperative morbidity and mortality after Fon- 
tan-type operations arc mainly related to low car- 
diac output associated with high CVP values as a 
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Table IlL Hemodynamic parameters, oxygen saturation and end tidal carbon dioxide values in four patients 
with bidirectional Glenn anastomosis after exposure to inhaled NO compared with baseline 
NO I NO 0 NO H 
CVP (mm Hg) 19 ± 1.5 (15-22) 24.5 ± 1.2 (21-26) 19.3 +_ 1.1 (16-21) 
LAP (mm Hg) 10 +_ 0.8 (8-12) 9 + 1.1 (6-11) 10 _+ 0.8 (8-12) 
TPG (ram Hg) 9 _+ 1.5 (5-12) 15.5 _+ 1.7 (11-19) 7 _+ 1.2 (4-9) 
SAP (mm Hg) 73 -+ 4 (66-84) 71 + 5 (64-85) 75 _+ 5 (67-86) 
HR (beats/min) 143 _+ 6 (132-154) 143 _+ 6 (131-155) 143 + 6 (131-155) 
Sao 2 (%) 78 +- 4 (67-83) 64 _+ 11 (31-76) 78 _+ 3 (69-81) 
Svo 2 (%) 66 _+ 5 (56-75) 59 _+ 6 (47-68) 66 _+ 6 (55-75) 
Petco 2 (mm Hg) 27 _+ 2.4 (20-30) 24.3 _+ 3 (16-29) 27 _+ 2 (20-30) 
Data are expressed as mean values plus or minus the standard error of mean (range). 
NO 1 and NO II, Exposures to NO; NO O, baseline; TPG, transpulmonary pressure gradient 
rate; Svo2, mixed venous blood oxygen saturation. 
(CVP - LAP); SAP, mean systemic arterial pressure; HR, heart 
result of elevated PVR, hypoplastic or distorted 
pulmonary arteries, or systemic ventricular dysfunc- 
tion.i2-14, 16 In the early postoperative p riod PVR is 
most labile because of pulmonary endothelial dys- 
function after cardiopulmonary b passY Thus even 
minor elevations of PVR may result in a severe 
impairment of pulmonary perfusion and conse- 
quently in low cardiac output syndrome. 16Aggres- 
sive mechanical ventilation may further decrease 
pulmonary perfusion. 24 Various intravenous vasodi- 
lators have been used to reduce elevated PVR 
values after cardiac operations, but all these agents 
also decrease systemic vascular esistance and may 
increase ventilation-perfusion mismatch in the pres- 
ence of additional parenchymal lung disease. 25' ~6 In 
contrast, inhaled NO acts only locally in the adjacent 
pulmonary smooth muscle cell producing selective 
pulmonary vasodilation and is rapidly inactivated by 
binding to hemoglobin in the circulation, which 
precludes ystemic vasoactive ffects. 27' 28 
In this study therapy with inhaled NO significantly 
improved hemodynamic conditions and arterial and 
venous oxygenation i patients with critical pulmo- 
nary perfusion in the early postoperative period 
after Fontan-type procedures and bidirectional 
Glenn anastomosis. In the patient group undergoing 
total cavopulmonary connection inhaled NO ther- 
apy decreased significantly elevated CVP and 
transpulmonary pressure gradients between CVP 
and LAP, whereas LAP increased. Although pulmo- 
nary blood flow was not measured, these hemody- 
namic changes together with the rise of levels of 
Sao 2 and of Petc02 indicate an improvement of 
pulmonary perfusion by selective lowering of post- 
operatively elevated PVR. Consequently the in- 
crease of pulmonary blood flow resulted in im- 
proved filling of the systemic ventricle associated 
with a significant rise of mean systemic arterial 
pressure, which may indicate together with the 
increase in venous oxygen saturation an improve- 
ment of cardiac output. However, the arteriovenous 
oxygen saturation difference, which might be the 
best indicator of cardiac output in this circumstance, 
did not change in our patients during NO inhalation 
therapy. 
In patients with fenestrated total cavopulmonary 
connection the reduction of the interatrial right-to- 
left shunt as a result of the decrease in CVP might 
have also contributed to the increase of Sao 2. Sim- 
ilar observations of improvement of hemodynamics 
and oxygenation i two patients after Fontan repair 
have been described by Miller, James, and Elliot 17 
and Yahagi and associates, i  
We also observed in our patients with bidirec- 
tional Glenn anastomosis a decrease in CVP and of 
transpulmonary pressure gradient and simulta- 
neously an increase in Sa02 after NO inhalation 
therapy, indicating an improvement of pulmonary 
perfusion. LAP and systemic arterial pressure values 
remained nearly unchanged. Because in the Glenn 
circulation inferior vena caval blood reenters the 
systemic circulation directly without passing the 
lungs, an improvement of pulmonary perfusion by 
inhaled NO therapy may only partially influence 
LAP and systemic ventricular preload, and conse- 
quently systemic arterial pressure. In contrast to our 
results Adatia and colleagues 2°reported no benefi- 
cial effect of inhaled NO on transpulmonary pres- 
sure gradients and Sa02 values in six patients after 
bidirectional Glenn anastomosis and suggested that 
PVR was not elevated in their patients. This expla- 
nation seems likely because the mean CVP value 
and transpulmonary pressure gradient in their pa- 
tients were 17 mm Hg and 8 mm Hg, respectively, 
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compared with a mean CVP value of 24.5 mm Hg 
and a mean transpulmonary pressure gradient of 
15.5 mm Hg in our patients. 
The systemic oxygen desaturation in our patients 
was mainly caused by the residual right-to-left shunt 
at the atrial level inasmuch as chest x-ray films and 
clinical observations excluded significant pulmonary 
parenchymal diseases. Because a postoperative ven- 
tilation-perfusion mismatch cannot be excluded in 
all our patients the improved oxygenation might be 
also related to an improvement of ventilation-per- 
fusion relationship by NO. 
We used a low-dose NO regimen between 1.5 and 
10 ppm; however, we did not perform dose-response 
testing. The effectiveness of low doses of inhaled 
NO for the treatment of adult respiratory distress 
syndrome, 29 persistent pulmonary hypertension in 
neonates, 6 and pulmonary hypertension after car- 
diac operations in children 9 has been reported pre- 
viously. In our study the doses of inhaled NO 
between 1.5 and 10 ppm were below recommended 
safety guidelines. 3° Methemoglobin levels measured 
several times daily and NO2 concentrations never 
reached clinically important values. The use of low 
doses of inhaled NO and a short duration of NO 
treatment reduce the risk of toxicity. Although we 
observed uniform hemodynamic reactions in all our 
patients after the start of NO therapy, our study may 
reflect the effects of withdrawal of NO rather than 
the hemodynamic effect of initiation of NO. One 
possible limitation of our study, however, is a known 
withdrawal phenomenon that transiently raises PVR 
even after a short exposure period of low-dose NO 
therapy. On the basis of our study design we cer- 
tainly cannot exclude this in our patients. 
In conclusion, this study demonstrates that in- 
haled NO even in low doses between 1.5 and 10 ppm 
improves critical pulmonary perfusion and oxygen- 
ation in the early postoperative period after Fontan- 
type procedures and bidirectional Glenn anastomo- 
sis. We suggest that this treatment might play an 
important role in the management of transient 
critical pulmonary perfusion caused by reactive ele- 
vated PVR levels after Fontan-type operations and 
bidirectional Glenn anastomosis. Nevertheless, fur- 
ther studies are required to show the impact of this 
new treatment on postoperative morbidity and clin- 
ical outcome of these operations. 
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